ExpreS2ion Biotech Holding

ExpreS2ion Biotech has today published the final terms for its previously announced fully pre-emptive rights issue with gross proceeds of approximately SEK 53 million before transaction costs.

ExpreS2ion today reported updated Phase I data showing consistent immune responses across dose levels. The independent DSMB recommends escalation to the 450 µg dose level and expansion of the 150 µg cohort, with no safety concerns identified.

ExpreS2ion has announced its intention to carry out a rights issue of units of approximately SEK 53 million before transaction costs, with each unit consisting of one new share and one TO 13 warrant exercisable in September 2026 at 70% of the prevailing VWAP. The issue is secured to approximately 60% through subscription and guarantee commitments, with an extraordinary general meeting scheduled for 1 April 2026, subscription period expected 16–30 April, and final terms to be set no later than 6 April based on a TERP discount of at least 35%. Proceeds are primarily earmarked to complete the Phase I dose-escalation (expected mid-2026) and expansion cohort (late 2026) of lead candidate ES2B-C001, its HER2-targeted breast cancer vaccine.

Last week, ExpreS2ion published its FY 2025 results, which on the financial side showed continued low cost and cash burn levels compared to a year ago. Towards the end of 2025 and into the beginning of 2026, the company has shown progress on both its own pipeline and partner-led programs. The main candidate ES2B-C001, its HER2-targeted therapeutic breast cancer candidate, has continued to show promising but very early data, and the Malaria and Nipah programs have continued to move forward.

Today, ExpreS2ion Biotechnologies’ management presented the financial results for the FY 2025, provided further insights into the recent pipeline developments with focus on the malaria, Niphah and breast cancer candidates, and shared the latest updates on partnerships agreements